Washington Trust’s BioMarin Pharmaceuticals BMRN Stock Holding History

Washington Trust’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-34	Closed	-$3K	–	928
2022 Q1	$3K	Sell	34 -57	-63%	-$4.77K	﹤0.01%	777
2021 Q4	$8K	Buy	91 +2	+2%	+$165	﹤0.01%	693
2021 Q3	$7K	Hold	89	–	–	﹤0.01%	814
2021 Q2	$7K	Hold	89	–	–	﹤0.01%	815
2021 Q1	$7K	Hold	89	–	–	﹤0.01%	785
2020 Q4	$8K	Hold	89	–	–	﹤0.01%	765
2020 Q3	$7K	Buy	89 +12	+16%	+$1.21K	﹤0.01%	762
2020 Q2	$9K	Sell	77 -24	-24%	-$2.38K	﹤0.01%	655
2020 Q1	$9K	Buy	+101	New	+$8.7K	﹤0.01%	677
2018 Q3	–	Sell	-39	Closed	-$4K	–	300
2018 Q2	$4K	Buy	+39	New	+$3.42K	﹤0.01%	763

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Washington Trust's BMRN Position: Q2 2022 in Review

Washington Trust sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2022, closing a stake of 34 shares — an estimated $3K sold.

Washington Trust first reported a position in BMRN in Q2 2018 and held it in 10 quarters. The position peaked at $9K in Q2 2020. 542 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

Washington Trust reported no remaining BioMarin Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Washington Trust sold 34 BioMarin Pharmaceuticals shares in Q2 2022, an estimated $3K.
Washington Trust first reported a position in BioMarin Pharmaceuticals in Q2 2018 and held it in 10 quarters.
Washington Trust's BioMarin Pharmaceuticals position peaked at $9K in Q2 2020.
542 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on Washington Trust's 13F filing for Q2 2022, filed 25 Jul 2022.